Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC
暂无分享,去创建一个
H. Groen | D. Planchard | J. Wolf | J. Mazières | C. Baik | B. Melosky | B. Johnson | Wen-Hsing Wu | F.A. Zadeh Vosta Kolaei | S. Knoll | Meryem Ktiouet Dawson | A. Johns
[1] Anala Gossai,et al. Validation analysis of a composite real‐world mortality endpoint for patients with cancer in the United States , 2021, Health services research.
[2] H. Rugo,et al. Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer , 2021, The oncologist.
[3] Jay J H Park,et al. Synthetic and External Controls in Clinical Trials – A Primer for Researchers , 2020, Clinical epidemiology.
[4] P. Xing,et al. Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer , 2020, Frontiers in Oncology.
[5] S. Baxi,et al. Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR , 2020 .
[6] S. Novello,et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Blay,et al. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] S. Toh,et al. Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions , 2020, Pharmacoepidemiology and drug safety.
[9] N. Hanna,et al. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Joshua Haimson,et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research , 2020, ArXiv.
[11] Jessica M Franklin,et al. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners , 2019, BMJ.
[12] A. Drilon,et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] J. Mosser,et al. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. , 2019, European journal of cancer.
[14] A. Iafrate,et al. Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer , 2018, Clinical Cancer Research.
[15] M. Mishaeli,et al. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check‐Point Inhibitors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[16] Stephen R Cole,et al. Transportability of Trial Results Using Inverse Odds of Sampling Weights. , 2017, American journal of epidemiology.
[17] K. Goldberg,et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond , 2017, The oncologist.
[18] D. Jayne,et al. SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .
[19] H. Groen,et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[20] Bastien Cabarrou,et al. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] J. Utikal,et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.
[22] Kari Lock Morgan,et al. Balancing Covariates via Propensity Score Weighting , 2014, 1609.07494.
[23] Jeanne Shen,et al. Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[24] Scott M Lippman,et al. Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.
[25] Antonio Marchetti,et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S Senan,et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] H. Groen,et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.
[28] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[29] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[30] Handra,et al. COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON–SMALL-CELL LUNG CANCER , 2001 .